Monopar de­lays IPO again de­spite slash­ing of­fer­ing while a mi­cro-cap biotech clinch­es $9M

Two low-pro­file bud­get biotechs have be­come the lat­est ca­su­al­ty of a weak IPO mar­ket. Monopar Ther­a­peu­tics is post­pon­ing its pub­lic de­but for a sec­ond time, where­as CNS Phar­ma­ceu­ti­cals raised a mea­ger $9 mil­lion by pric­ing at the low end of the range.

By the time Monopar came around to fil­ing its sec­ond pitch, it had al­ready slashed its goal (and the num­ber of shares of­fered) by half — seek­ing to bag $20 mil­lion in­stead of $40 mil­lion it had orig­i­nal­ly pro­posed in Au­gust. But even that proved to be a stretch.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.